Puma Biotechnology falls more than 20%
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma (PBYI): Recent Rally Looks Overdone, Unsupported With Fundamentals | Seeking Alpha
Alan H. Auerbach - Los Angeles Business Journal
Should You Buy Puma Biotechnology Inc (PBYI) Stock Tuesday?
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Here's Why Puma Biotechnology Fell 17.2% in April | The Motley Fool
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
PumaBiotech on Twitter: "Puma Biotechnology is dedicated to developing innovative, new treatments to help #cancer patients. As part of our ongoing commitment to the cancer community, we're proud to have participated in #
News Release
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Surging
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
